Psoriasis — Trials, FDA Actions & Pivotal Research
14 updates aggregated from openFDA and ClinicalTrials.gov, covering trial milestones, FDA actions, and pivotal publications about Psoriasis.
Synced daily from openFDA and ClinicalTrials.gov. Last sync: .
Drugs with Psoriasis trials
Recruiting trials by city
Cities where Psoriasis trials in our archive had recruiting sites. Each link lists every currently recruiting paid clinical trial at that location.
Updates
2026
- Primary completionDeucravacitinib Plaque Psoriasis Trial vs. Zasocitinib Completes Primary Phase· Apr 22, 2026· drug: Deucravacitinib
- Results postedSecukinumab + Lifestyle Intervention Improves Psoriasis, Cardiometabolic Markers· Apr 22, 2026· drug: Secukinumab
- Primary completionSecukinumab Biosimilar Trial for Plaque Psoriasis Completes Phase 3 Primary…· Feb 18, 2026· drug: Secukinumab
- Primary completionIxekizumab Phase 3 Trial for Psoriasis and Obesity Completes Primary Phase· Jan 8, 2026· drug: Ixekizumab
2025
- Results postedTofacitinib Reduces IFN Signaling, Improves Skin Conditions in Down Syndrome· Dec 11, 2025· drug: Tofacitinib
- Results postedRisankizumab High-Dose Psoriasis Trial Shows Reduced Skin T Cells· Oct 24, 2025· drug: Risankizumab
- Results postedDeucravacitinib Significantly Improves QoL in Plaque Psoriasis Trial· Sep 10, 2025· drug: Deucravacitinib
- Results postedIxekizumab Hits 86% PASI-75 in Plaque Psoriasis, 84% ACR20 in Psoriatic…· Aug 22, 2025· drug: Ixekizumab
- Results postedRimegepant Phase 2 Trial for Psoriasis Shows No Improvement Over Placebo· Jul 17, 2025· drug: Rimegepant
- Primary completionSecukinumab: Phase 3 Comparative Study for Plaque Psoriasis Completes· Jun 30, 2025· drug: Secukinumab
- Results postedSecukinumab Trial: Psoriasis Patients Show Changes in Itch and Pain Scores· Jun 5, 2025· drug: Secukinumab
- Results postedInfliximab Biosimilar 3 Safety Data Posted for Rheumatoid Arthritis· Jun 4, 2025
- Primary completionGuselkumab Phase 3 Psoriasis Trial in Skin of Color Completes Primary Data· May 30, 2025· drug: Guselkumab
- Results postedRisankizumab Phase 3 Trial: Pediatric Plaque Psoriasis PASI 75 Rates Up to 92.3%· May 20, 2025· drug: Risankizumab